IFM Therapeutics is developing therapeutics to treat patients with autoimmune diseases. The innate immune system is the body’s first line of defense and an underlying driver of many autoimmune diseases and cancers. IFM is creating drug candidates for targets validated by human genetics that address the underlying disease drivers, bringing precision medicine to immunology. For cancer therapies, IFM is finding targets that can synergise with checkpoint inhibitors. Each of IFMs programs is targeting key nodes of the innate immune system with each program having individual financial support and focused research.

IFM Therapeutics (2)

Founded: 2017
Location: Boston, MA
Employee range: 11 - 50
Clinical stage: Clin?
Therapy area: Immuno-oncology
Drug types: ONC, IMM, NEU, GI
Lead product: IFM UNO (rights to Bristol Myers Squibb)
Funding: $55.5M Dec 2019

Drug notes:

About:

Jobs: